FY2024 EPS Estimates for AC Immune Lifted by HC Wainwright

AC Immune SA (NASDAQ:ACIU) – Equities researchers at HC Wainwright increased their FY2024 earnings estimates for shares of AC Immune in a research report issued on Wednesday, November 6th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.62) per share for the year, up from their previous estimate of ($0.91). HC Wainwright currently has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for AC Immune’s current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for AC Immune’s Q4 2024 earnings at ($0.23) EPS, FY2025 earnings at $0.41 EPS, FY2026 earnings at $0.75 EPS, FY2027 earnings at $1.36 EPS and FY2028 earnings at $1.95 EPS.

AC Immune (NASDAQ:ACIU) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.67). The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $91.60 million.

Separately, StockNews.com downgraded shares of AC Immune from a “buy” rating to a “hold” rating in a report on Tuesday, October 1st.

AC Immune Stock Performance

ACIU opened at $3.20 on Friday. AC Immune has a twelve month low of $2.25 and a twelve month high of $5.14. The business has a 50 day moving average price of $3.27 and a 200 day moving average price of $3.45. The firm has a market cap of $316.61 million, a P/E ratio of -4.44 and a beta of 1.28.

Institutional Trading of AC Immune

A number of hedge funds have recently bought and sold shares of ACIU. China Universal Asset Management Co. Ltd. increased its position in shares of AC Immune by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock valued at $72,000 after purchasing an additional 7,400 shares during the period. Cubist Systematic Strategies LLC bought a new stake in AC Immune in the 2nd quarter valued at $218,000. Renaissance Technologies LLC raised its stake in shares of AC Immune by 26.4% in the 2nd quarter. Renaissance Technologies LLC now owns 652,079 shares of the company’s stock valued at $2,602,000 after buying an additional 136,300 shares in the last quarter. Vanguard Capital Wealth Advisors bought a new position in shares of AC Immune during the 2nd quarter worth about $56,000. Finally, Assenagon Asset Management S.A. boosted its position in shares of AC Immune by 294.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 439,730 shares of the company’s stock valued at $1,755,000 after acquiring an additional 328,312 shares in the last quarter. 51.36% of the stock is owned by institutional investors.

About AC Immune

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.